Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.55 USD | 0.00% | -4.64% | -7.14% |
May. 17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.14% | 18.45M | |
+33.76% | 693B | |
+29.39% | 584B | |
-2.90% | 372B | |
+20.45% | 332B | |
+6.77% | 294B | |
+14.30% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+9.33% | 168B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Transcript : Kala Pharmaceuticals, Inc., Q1 2020 Earnings Call, May 07, 2020